Akatinol Memantine, 5 mg+10 mg+15 mg+20 mg 7 pcs.

Pharmgroup:

A treatment for dementia

Pharm Action:

As a noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist, it has modulatory effects on the glutamatergic system.

It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics:

Akatinol Memantine is quickly and completely absorbed after oral administration. Maximum plasma concentration is reached within 2-6 hours. No cumulation of the drug is noted with normal renal function.

Extraction is biphasic. Period of semiejection half-life is 4-9 hours in the first phase and 40-65 hours in the second phase. It is excreted with urine.

Indications

Degenerative dementia (Alzheimer’s type), vascular dementia, mixed dementia of all degrees of severity. Alzheimer’s disease, Pick’s disease
Dementia syndrome, depressive states in dementia
Decreased memory, concentration and learning ability
Diseases that require increased vigilance, for example, after traumatic brain injury, open or closed brain damage, coma, coma

Pharmacological effect

Pharmaceutical group:

Dementia Treatment

Pharmaceutical action:

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system.

Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics:

After oral administration, Akatinol Memantine is quickly and completely absorbed. The maximum concentration in blood plasma is achieved within 2–6 hours. With normal renal function, no accumulation of the drug was observed.

Excretion occurs in two phases. The half-life is 4–9 hours in the first phase, 40–65 hours in the second phase. It is excreted in the urine.

Special instructions

For patients with impaired renal function, the dosage regimen is set individually, depending on clinical effectiveness, under the control of renal function during treatment.

When used together, Akatinol Memantine may change the effect of dantrolene or baclofen, so the doses of the drugs should be selected individually.

Patients with Alzheimer’s disease in the stages of moderate to severe dementia usually have impaired ability to drive or operate machinery.

Active ingredient

Memantine

Composition

1 film-coated tablet contains:

active substance:

memantine hydrochloride 5, 10, 15, 20 mg;

excipients:

lactose,

MCC,

colloidal silicon dioxide,

talc,

magnesium stearate,

shell:

methacrylic acid copolymer, sodium lauryl sulfate, talc

Contraindications

individual hypersensitivity to the drug Akatinol Memantine;
severe renal dysfunction;
pregnancy;
breast-feeding;
children under 18 years of age (due to insufficient data).

With caution:

thyrotoxicosis;
epilepsy;
convulsions (including history);
myocardial infarction;
heart failure.

Side Effects

Adverse reactions are classified according to clinical manifestations (according to damage to certain organ systems) and frequency of occurrence:

From the body as a whole – common adverse reactions

Often Headache

Rarely Fatigue

Infections

Rarely Fungal infections

Mental disorders

Often Drowsiness

Rare: Confusion

Rarely Hallucinations

Frequency not set

Psychotic reactions

Cardiovascular disorders

Rarely Hypertension

Rare: Venous thrombosis/thromboembolism

Gastrointestinal disorders

Often Constipation

Rarely Nausea, vomiting

Frequency not established Pancreatitis

Disorders of the central and peripheral nervous system

Often Dizziness

Rare Gait disturbance

Very rare Convulsions

Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

There are isolated reports of the occurrence of these adverse reactions when using the drug in clinical practice (data obtained after the drug was marketed).

Interaction

With the simultaneous use of Akatinol Memantine with L-dopa drugs, dopamine agonists, and anticholinergics, the effect of the latter may be enhanced.

When used simultaneously with barbiturates and neuroleptics, the effect of the latter may decrease.

When used together, change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be selected individually.

Concomitant use with amantadine, ketamine and dexamethophan should be avoided.

Plasma levels of cimetidine, procainamide, kinidine, kinin and nicotine may increase when taken simultaneously with memantine.

It is possible to reduce the level of hydrochlorothiazide when taken simultaneously with memantine.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

4 years

Manufacturer

Rottendorf Pharma GmbH, Germany